CL2012000726A1 - Metodo para preparar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes, topicas, cargadas con agente activo que comprende combinar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes con agente activo en presencia de solvente no acuoso y luego separar el solvente por evaporacion. - Google Patents

Metodo para preparar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes, topicas, cargadas con agente activo que comprende combinar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes con agente activo en presencia de solvente no acuoso y luego separar el solvente por evaporacion.

Info

Publication number
CL2012000726A1
CL2012000726A1 CL2012000726A CL2012000726A CL2012000726A1 CL 2012000726 A1 CL2012000726 A1 CL 2012000726A1 CL 2012000726 A CL2012000726 A CL 2012000726A CL 2012000726 A CL2012000726 A CL 2012000726A CL 2012000726 A1 CL2012000726 A1 CL 2012000726A1
Authority
CL
Chile
Prior art keywords
uniform
rigid
active agent
nanoporous
calcium phosphate
Prior art date
Application number
CL2012000726A
Other languages
English (en)
Inventor
Tetsuro Ogawa
Akira Yamamoto
Original Assignee
Laboratory Skin Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratory Skin Care Inc filed Critical Laboratory Skin Care Inc
Publication of CL2012000726A1 publication Critical patent/CL2012000726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/0279—Porous; Hollow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN DESCRIBE UN MÉTODO PARA PREPARAR PARTÍCULAS DE FOSFATO DE CALCIO NANOPOROSAS, ESFÉRICAS, RÍGIDAS, UNIFORMES, TÓPICAS CARGADAS CON AGENTE ACTIVO, QUE COMPRENDE COMBINAR PARTÍCULAS DE FOSFATO DE CALCIO NANOPOROSAS, ESFÉRICAS,<br /> RÍGIDAS, UNIFORMES CON UN AGENTE ACTIVO EN PRESENCIA DE UN SOLVENTE NO ACUOSO Y LUEGO SEPARAR EL SOLVENTE NO ACUOSO DE LAS PARTÍCULAS DE FOSFATO DE CALCIO NANOPOROSAS, ESFÉRICAS, RÍGIDAS, UNIFORMES, CARGADAS CON AGENTE ACTIVO; Y DONDE LA PARTÍCULA DE FOSFATO DE CALCIO NANOPOROSA, ESFÉRICA, RÍGIDA, UNIFORME TIENE UN DIÁMETRO QUE OSCILA ENTRE 1 Y 10 UM Y DONDE EL SOLVENTE NO ACUOSO SE SEPARA DE LAS PARTÍCULAS DE FOSFATO DE CALCIO NANOPOROSAS, ESFÉRICAS, RÍGIDAS, UNIFORMES, CARGADAS CON AGENTE ACTIVO POR EVAPORACIÓN DEL SOLVENTE NO ACUOSO.<br />  
CL2012000726A 2008-09-23 2012-03-23 Metodo para preparar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes, topicas, cargadas con agente activo que comprende combinar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes con agente activo en presencia de solvente no acuoso y luego separar el solvente por evaporacion. CL2012000726A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9950008P 2008-09-23 2008-09-23
PCT/US2009/058108 WO2010039560A2 (en) 2008-09-23 2009-09-23 Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same

Publications (1)

Publication Number Publication Date
CL2012000726A1 true CL2012000726A1 (es) 2013-01-11

Family

ID=42074119

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000726A CL2012000726A1 (es) 2008-09-23 2012-03-23 Metodo para preparar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes, topicas, cargadas con agente activo que comprende combinar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes con agente activo en presencia de solvente no acuoso y luego separar el solvente por evaporacion.

Country Status (17)

Country Link
US (5) US8535723B2 (es)
EP (1) EP2480210A4 (es)
JP (1) JP5730316B2 (es)
KR (4) KR20160083953A (es)
CN (1) CN102802610A (es)
AU (1) AU2009298814B2 (es)
BR (1) BR112012006635B8 (es)
CA (1) CA2778604C (es)
CL (1) CL2012000726A1 (es)
EA (1) EA027992B1 (es)
IL (2) IL218808A (es)
MX (1) MX356209B (es)
MY (1) MY162982A (es)
NZ (1) NZ599544A (es)
SG (2) SG10201903125QA (es)
WO (1) WO2010039560A2 (es)
ZA (1) ZA201202948B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480210A4 (en) * 2008-09-23 2016-07-13 Lab Skin Care Inc ACTUATED UNIFORMS, RIGID, SPHERICAL NANOPOROUS CALCIUMOPHOSPHATE PARTICLES AND METHOD FOR THEIR USE AND MANUFACTURE
PL2413902T3 (pl) * 2009-03-18 2020-01-31 Incarda Therapeutics, Inc. Dawki jednostkowe, aerozole, zestawy oraz sposoby leczenia chorób serca przez podawanie dopłucne
ES2942923T3 (es) * 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
KR20120056824A (ko) * 2009-08-19 2012-06-04 바이엘 파마 악티엔게젤샤프트 소아과 용도를 위한 약물 전달 시스템 （웨이퍼）
CN102905675B (zh) * 2009-11-10 2018-11-16 护肤品实验室有限公司 包含均匀、硬质、球形、纳米多孔磷酸钙颗粒的防晒剂组合物及其制备和使用方法
EP2665483B1 (en) * 2011-01-19 2020-08-26 Laboratory Skin Care, Inc. Topical minocycline compositions and methods of using the same
CN107875391A (zh) * 2011-08-16 2018-04-06 实验室护肤股份有限公司 细干颗粒腺苷组合物和包括其的局部制剂
CN102552913B (zh) * 2012-01-19 2013-06-19 中国科学院上海硅酸盐研究所 一种纳米结构磷酸钙双载药体系及其制备方法
CN103284929B (zh) * 2012-02-23 2015-08-12 黄曦 一种护肤品及其制备方法
US11844852B2 (en) * 2012-02-23 2023-12-19 Fe:I Beauty Tech, Inc. Skincare product and method of preparation thereof
CN102579355B (zh) * 2012-03-19 2013-03-06 天津大学 米托蒽醌纳米磷酸氢钙制剂及其制备方法
CZ2012724A3 (cs) * 2012-10-24 2014-07-23 Agra Group, A.S. Mezoporézní částice, jejich použití a přípravek je obsahující
NZ713342A (en) * 2013-03-15 2020-12-18 Laboratory Skin Care Inc Fine dry particulate retinoid active agent compositions and topical formulations including the same
MY175420A (en) 2013-03-15 2020-06-24 Laboratory Skin Care Inc Fine dry particulate resveratrol active agent compositions and topical formulations including the same
CN104856889B (zh) * 2014-09-22 2017-05-10 北京大学口腔医学院 缓释氯己定无定形磷酸钙纳米颗粒的制备方法
CN105336873B (zh) * 2015-11-05 2018-12-07 广州竞择微电子技术有限公司 一种柔性光电子器件用基板及其制备方法
CN114847965A (zh) 2016-02-01 2022-08-05 英凯达治疗公司 电子监测联合吸入药理学疗法管理心律失常
CA3026041A1 (en) * 2016-06-03 2017-12-07 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2018134783A1 (en) 2017-01-20 2018-07-26 M et P Pharma AG Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
AU2018266199A1 (en) 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
JP6961504B2 (ja) * 2018-01-26 2021-11-05 国立大学法人 岡山大学 徐放性デバイス
EP3768378A4 (en) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE
KR102221493B1 (ko) * 2018-12-12 2021-02-26 성균관대학교산학협력단 핵산 기반의 칼슘 포스페이트 나노 소재를 합성하는 방법 및 이에 의해 합성된 핵산 기반의 칼슘 포스페이트 나노 소재
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN113054121B (zh) * 2019-12-28 2022-07-05 Tcl科技集团股份有限公司 纳米材料及其制备方法、半导体器件

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5158756A (en) 1989-06-24 1992-10-27 Asahi Kogaku Kogyo Kabushiki Kaisha Porous particles of calcium phosphate compound and production process thereof
JPH07330319A (ja) * 1994-06-03 1995-12-19 Asahi Optical Co Ltd 皮膚清浄用粉末組成物
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US6096324A (en) * 1995-06-13 2000-08-01 Laboratory Skin Care Methods of delivering materials into the skin, and compositions used therein
US6579516B1 (en) * 1995-06-13 2003-06-17 Zahra Mansouri Methods of delivering materials into the skin, and compositions used therein
US6416774B1 (en) * 1996-05-09 2002-07-09 The Trustees Of The University Of Pennsyvania Hollow bone mineral-like calcium phosphate particles
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
AUPQ573300A0 (en) * 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
JP2004075662A (ja) * 2002-06-20 2004-03-11 Mukku:Kk 徐放性組成物、その製造方法およびその製剤
WO2004112751A1 (ja) 2003-06-18 2004-12-29 Ltt Bio-Pharma Co., Ltd. 薬物含有徐放性微粒子、その製造法、及びそれを含有する製剤
FR2856594B1 (fr) * 2003-06-26 2006-03-03 Oreal Particules poreuses chargees en compose(s) actif(s) cosmetique(s) ou pharmaceutique(s)
US20050031559A1 (en) 2003-07-07 2005-02-10 L'oreal Cosmetic composition for caring for and/or making up skin
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
BRPI0507680A (pt) 2004-02-13 2007-07-17 Nod Pharmaceuticals Inc partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
EP1737378A2 (en) * 2004-04-02 2007-01-03 Baylor College of Medicine Novel modification of medical prostheses
US20060073205A1 (en) * 2004-10-04 2006-04-06 Kotoe Ohta Controlled release granules comprising porous silica core
US20060257492A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
CN1813657A (zh) * 2005-12-15 2006-08-09 孙振淋 纳米磷酸钙类盐在化妆产品中的应用方法
CN100509695C (zh) * 2006-02-21 2009-07-08 西南交通大学 多孔羟基磷灰石和磷酸钙陶瓷的制备方法
FR2898807B1 (fr) * 2006-03-23 2008-12-05 Oreal Composition comprenant de l'hydroxyapatite et un sel de calcium pour renforcer la fonction barriere de la peau et/ou des semi-muqueuses
CN100460016C (zh) * 2006-04-21 2009-02-11 华南理工大学 介孔磷酸钙纳米颗粒及其制备方法和应用
EP2480210A4 (en) * 2008-09-23 2016-07-13 Lab Skin Care Inc ACTUATED UNIFORMS, RIGID, SPHERICAL NANOPOROUS CALCIUMOPHOSPHATE PARTICLES AND METHOD FOR THEIR USE AND MANUFACTURE
ES2942923T3 (es) * 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
NZ713342A (en) * 2013-03-15 2020-12-18 Laboratory Skin Care Inc Fine dry particulate retinoid active agent compositions and topical formulations including the same

Also Published As

Publication number Publication date
MY162982A (en) 2017-07-31
US8535723B2 (en) 2013-09-17
CA2778604C (en) 2021-10-05
EP2480210A2 (en) 2012-08-01
EA201290170A2 (ru) 2012-11-30
KR20160083953A (ko) 2016-07-12
IL218808A (en) 2017-10-31
IL218808A0 (en) 2012-06-28
AU2009298814B2 (en) 2016-05-05
US10028903B2 (en) 2018-07-24
WO2010039560A2 (en) 2010-04-08
BR112012006635B1 (pt) 2021-04-06
BR112012006635A2 (pt) 2016-05-03
KR20180089553A (ko) 2018-08-08
EP2480210A4 (en) 2016-07-13
US20210015739A1 (en) 2021-01-21
SG10201903125QA (en) 2019-05-30
AU2009298814A1 (en) 2012-06-21
US20190117558A1 (en) 2019-04-25
SG10201406431QA (en) 2014-11-27
KR101689635B1 (ko) 2016-12-26
MX2012003542A (es) 2012-09-07
WO2010039560A3 (en) 2015-05-21
IL255112A0 (en) 2017-12-31
ZA201202948B (en) 2014-08-27
BR112012006635B8 (pt) 2021-05-25
EA027992B1 (ru) 2017-09-29
IL255112B (en) 2019-09-26
US20240082147A1 (en) 2024-03-14
EA201290170A3 (ru) 2013-03-29
US20140199400A1 (en) 2014-07-17
NZ599544A (en) 2014-04-30
US10758478B2 (en) 2020-09-01
KR20120104188A (ko) 2012-09-20
CN102802610A (zh) 2012-11-28
MX356209B (es) 2018-05-18
CA2778604A1 (en) 2010-04-08
JP5730316B2 (ja) 2015-06-10
KR20170096241A (ko) 2017-08-23
JP2013505293A (ja) 2013-02-14
US20100086606A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
CL2012000726A1 (es) Metodo para preparar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes, topicas, cargadas con agente activo que comprende combinar particulas de fosfato de calcio nanoporosas, esfericas, rigidas, uniformes con agente activo en presencia de solvente no acuoso y luego separar el solvente por evaporacion.
AR113031A1 (es) Composiciones de nanopartículas lipídicas (lnp) que comprende arn
CL2019003432A1 (es) Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de ciclooxigenasa (cox) o un fármaco antiinflamatorio no esterioidal (aine), y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
AR069482A1 (es) Proceso para producir un toner
PE20161103A1 (es) Dispositivos y metodos de reciclaje de baterias acidas de plomo sin necesidad de fundicion
CL2011001419A1 (es) Procedimiento para separar por lo menos un primer material de una mezcla, que comprende contactar la mezcla con una sustancia de superficie activa, tratar la dispersión con partículas magnéticas hidrófobas para que formen aglomerados con el primer material y la sustancia, separar los aglomerados y disociar dichos aglomerados
BR112014005442A2 (pt) bateria secundária de eletrólito não aquoso
ES2723201T3 (es) Inyector de haces neutros basado en iones negativos
BR112014004460A2 (pt) material polimérico para um recipiente isolado
BR112013030584A2 (pt) sistema e método para preservar referências em sandboxes
GB2547120A (en) A multi-reflecting time-of-flight analyzer
AR084783A1 (es) Producto desulfurante resistente a la aglomeracion
ECSP20081995A (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
DOP2010000114A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea
EP3486633A3 (en) Preparation of cryogenic sample for charged-particle microscopy
CL2009001080A1 (es) Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.
UA112988C2 (uk) Тютюновий матеріал, що містить неізометричні мікрочастинки карбонату кальцію
CL2011000393A1 (es) Metodo para preparar una microesfera de liberacion sostenidaque comprende disolver la sustancia activa y un polimero biodegradable en solvente acuoso y no acuoso respectivamente, formar una emulsion entre ambas soluciones, adicionarle un cosolvente y agregarla a un solvente acuoso para formar la microesfera y remover el solvente organico.
BR112012010026A2 (pt) dispositivo oculares de entrega de drogas
UA112540C2 (uk) Плівкова лікарська форма, яка містить вільну основу силденафілу, і спосіб її отримання
AR075716A1 (es) Separacion magnetica de minerales metalicos no ferrosos por acondicionamiento en multiples etapas
AR090997A1 (es) Aparato para la separacion con poco uso de recursos de particulas magneticas a partir de particulas no magneticas
AR073056A1 (es) Mejoras relacionadas a composiciones nanodispersas.
BR112012017151A2 (pt) unidade e dispositivo para a preparação de células e/ou partículas em um líquido e método para análise microscópica
AR118418A1 (es) Conservación de partículas ifa revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspensión acuosa